IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...

March 9 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday a small number of basic Medicare drug plans may not follow the $50 per month ‌cap on out-of-pocket costs for its weight-loss drugs, ...

The Kansas City Chiefs wasted no time signing former Seattle Seahawks running back Kenneth Walker III when the legal tampering period of free agency began on Monday, March 9. Walker, who won Super ...

Eli Lilly is a market darling at the moment because of its industry-leading GLP-1 drugs. The stock looks priced for perfection despite a well-known drug cycle. That's good news, but investors are well ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now. There’s been huge hype around AI’s potential for drug discovery. But at Eli Lilly, ...

Eli Lilly is a market darling at the moment because of its industry-leading GLP-1 drugs. The stock looks priced for perfection despite a well-known drug cycle. 10 stocks we like better than Eli Lilly ...

Novo Nordisk shares sank after the Danish drugmaker suffered a setback in its battle with Eli Lilly to dominate the market for weight-loss drugs.

Novo Nordisk announced its CagriSema GLP-1 weight loss drug underperformed Eli Lilly's tirzepatide in a trial. Separately, Lilly announced patients can use a single injector to hold a month's supply ...

Novo Nordisk’s experimental weekly shot CagriSema was shown to lead to less dramatic weight loss compared to rival Lilly’s Tirzepatide, the drug behind Zepbound and Mounjaro, in an 84-week trial, Novo ...

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some ...

CagriSema shows 23% weight loss versus 25.5% for Zepbound Novo's shares drop 15% Lilly's shares rise 4% in US pre-market trading Outcome is 'worst-case scenario' for Novo, investor says Few analysts ...